Aminsharifi A, et al. - Authors evaluated the predictive value of prostate-specific antigen density (PSAD) to detect clinically significant prostate cancer (prostate cancer grade group (GrGp) ≥2) in a series of men undergoing prostate biopsy with PSA 4-10 ng/mL. They defined an optimum cut-point for PSAD and ascertained how race and body mass index (BMI) affected PSAD performance. Findings suggested that regardless of race or BMI, it was unlikely for the men with a PSAD <0.08 to harbor GrGp ≥2 disease when PSA is 4-10 ng/mL. PSAD, if validated was a simple inexpensive and available tool. This could be used to identify men who can likely forego prostate biopsies, therefore reducing over-detection and morbidity from unnecessary biopsies.